Immunovant, Inc. IMVT
Updated: 10 Sep 2026
No signal published yet
We already track Immunovant and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Immunovant, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immunovant free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Immunovant reported its financial results for the fiscal first quarter ended June 30, 2026, and highlighted corporate updates on its anti-FcRn therapy IMVT-1402 across six autoimmune indications. The company held $797.8 million in cash and cash equivalents to support its clinical developments. On September 2, 2026, stockholders approved all proposals at the company's annual meeting.
What Firelda Watch includes for Immunovant, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Immunovant, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immunovant free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more